Friday, 19 Jul 2019

You are here

What To Do After Teriparatide?

Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?

A one-year observational study compared switching from daily TPTD to either oral bisphosphonates (BP) therapy or denosumab (DMAb) in patients with primary osteoporosis. Postmenopausal patients (n=78) with a mean age 76.3 years, had taken TPTD therapy for 20.1 (6-24) months  were allocated to either the BP or DMAb groups based on physician's decision. BMD and serum bone turnover markers were monitored every 6 months.

Groups were well matched at baseline and after 12 months. The increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6%; P<0.01), total hip (4.2 vs. 1.1%; P<0.05), and femoral neck (3.5 vs. 1.4%; P<0.05). The DMAb group showed a significant decrease in some bone turnover markers (TRACP-5b [-55.8 vs. -32.8%; P<0.01] and ucOC [-85.5 vs. -65.0%; P<0.001], but not PINP (-67.5 vs. -62.1%).

In this open-label observational study, switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption markers compared to switching to oral BP at 12 months, and thus may next best option after daily TPTD treatment.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis of the knee. A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg.

Increased Risk of Cardiovascular Death in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis patients have been shown to have increased mortality rates from cardiovascular events when compared to the general population.

The study included patients in the Skåne Healthcare Register from southern Sweden who were 45–84 years old and seen over 2004-2014. Overall, there were 15,901 such patients in the study.

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age.